Live Analyst Rating Changes 20525 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Graham Parry
Citi

Graham Parry

Citi
Wall Street Analyst
★★☆☆☆
#2177
on 13Foresight · ranked by our own returns
48%
Success Rate
-2.7%
Average Return
13 of 27 calls profitable · -11.0% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 48% of Graham Parry's ratings turned a profit when each position was held for 1 year — averaging -2.7% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

25 Buy 16 Hold 0 Sell
Graham's Stock Coverage 16 ratings · 2026-08-07
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
GB:AZN
AstraZeneca
 Aug 04, 2026 BUY Strong Buy
+21.8% avg upside
26 analysts
 — -1.5% ·
GB:GSK
GlaxoSmithKline
 Jul 29, 2026 HOLD Hold
-0.9% avg upside
25 analysts
$2100.00
8.45% Upside
 -0.2% ·
CH:NOVN
Novartis AG
 Jul 22, 2026 BUY Buy
-10.8% avg upside
32 analysts
$142.00
13.53% Upside
 -1.9% ·
GB:0QIU
Novo Nordisk
 Jul 20, 2026 HOLD Hold
+39.5% avg upside
29 analysts
$330.00
11.69% Upside
 · ·
CH:ROP
Roche Holding AG
 Mar 10, 2026 BUY Buy
-9.1% avg upside
23 analysts
 — +13.9% ·
FR:SAN
Sanofi
 Feb 20, 2026 HOLD Strong Buy
+31.4% avg upside
30 analysts
$80.00
7.57% Upside
 -2.8% ·
SNY
Sanofi
 Jan 31, 2025 BUY Strong Buy
+72.0% avg upside
20 analysts
 — -9.6% ·
GSK
GlaxoSmithKline
 Dec 06, 2024 SELL Hold
-15.9% avg upside
19 analysts
$19.06
63.29% Downside
 -46.1% ·
NVS
Novartis
 Sep 11, 2024 HOLD Hold
-13.4% avg upside
24 analysts
$130.00
15.46% Downside
 +14.9% ·
ES:GRF
Grifols
 Sep 12, 2023 BUY Buy
+45.8% avg upside
12 analysts
$20.00
97.91% Upside
 -20.9% ·
GB:HLN
Haleon PLC
 Mar 07, 2023 BUY Strong Buy
+19.8% avg upside
20 analysts
$614.68
65.78% Upside
 +2.0% ·
GILD
Gilead Sciences
 Mar 03, 2023 HOLD Strong Buy
-9.1% avg upside
66 analysts
$88.00
32.37% Downside
 -7.4% ·
PFE
Pfizer
 Feb 28, 2023 HOLD Buy
+28.1% avg upside
45 analysts
$50.00
93.37% Upside
 -29.9% ·
RHHBY
Roche Holding
 Sep 10, 2018 HOLD Buy
-11.5% avg upside
14 analysts
$34.00
39.43% Downside
 +15.4% ·
GMAB
Genmab
 Sep 10, 2018 SELL Buy
+20.1% avg upside
27 analysts
 — -21.1% ·
TRVG
trivago
 Oct 26, 2017 SELL Hold
-9.6% avg upside
15 analysts
 — +17.4% ·
🔒 11 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Graham Parry — Frequently Asked Questions
How accurate are Graham Parry's stock ratings?
Based on the calls 13Foresight could measure, about 48% of Graham's ratings were profitable over a one-year hold, with an average return of -2.8% per rating, or -11.7% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Graham ranked on 13Foresight?
Graham Parry is currently ranked #2177 with a 2-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Graham cover?
Graham most recently has ratings on GB:AZN, GB:GSK, CH:NOVN, GB:0QIU, CH:ROP, FR:SAN, SNY, GSK, NVS, ES:GRF, GB:HLN, GILD and 4 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.